agree with most of your points in that post. thanks for contributing. yes, things have blown out, since 'that' announcement, such is the nature of biotech. PRV, sure, a bonus, but not a focus for me right now.
dont have time to do proper research but from a glance it looks like your saying 'getting to trial with current burn rate' when we all know very clearly we need more funds. I see about $400k per quarter being spent on running costs, excluding trial.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-32
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.0¢ |
Change
0.003(3.90%) |
Mkt cap ! $72.12M | |||
| Open | High | Low | Value | Volume |
| 7.9¢ | 8.3¢ | 7.9¢ | $147.1K | 1.826M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300000 | 7.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.3¢ | 106165 | 2 |
View Market Depth
| Last trade - 16.10pm 08/05/2024 (20 minute delay) ? |
|
|||||
|
Last
8.0¢ |
Change
0.003 ( 3.90 %) |
||||
| Open | High | Low | Volume | ||
| 7.9¢ | 8.3¢ | 7.9¢ | 108394 | ||
| Last updated 15.59pm 08/05/2024 ? | |||||
| PER (ASX) Chart |